Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Living Brain Cells Generated from Biobanked Brain Tissue

By BiotechDaily International staff writers
Posted on 21 Jan 2014
Scientists for the first time have generated induced pluripotent stem (iPS) cells lines from non-cryoprotected brain tissue of Alzheimer’s disease (AD) patients.

These new stem cell lines will allow researchers to “turn back the clock” and observe how Alzheimer’s develops in the brain, potentially illuminating the start of the disease at a cellular level way before any symptoms tied to AD are shown. These reconstituted Alzheimer’s cells will also provide a platform for drug testing on cells from patients that were conclusively diagnosed with the disease. Up to now, the only available way to conclusively diagnose AD that has been available to researchers is studying the brain of deceased patients. This discovery will allow scientists for the first time to compare “live” brain cells from Alzheimer’s patients to the brain cells of other non-Alzheimer’s patients.

Scientists from New York Stem Cell Foundation Research Institute (NYSCF; New York, NY, USA), working in collaboration with scientists from Columbia University Medical Center (New York, NY, USA), have effectively generated the iPS cells from frozen tissue samples stored for up to 11 years, and published their findings January 7, 2014, in the journal Acta Neuropathologica Communications, revealed that disease-specific iPS cells can be generated from readily available biobanked tissue that has not been cryoprotected, even after they have been frozen for many years. This allows for the generation of iPS cells from brains with confirmed disease pathology as well as allows access to rare patient variants that have been banked. Moreover, findings made using iPS cellular models can be cross-validated in the original brain tissue used to generate the cells. The stem cell lines generated for this study included samples from patients with confirmed AD and four other neurodegenerative diseases.

This noteworthy accomplishment creates new avenues to research cells affected by disease from patients with definitive diagnoses. This advance will utilize existing biobanks to support research in an effective new way.

iPS cells are typically generated from a skin or blood sample of a patient by turning back the clock of adult cells into pluripotent stem cells, cells that can become any cell type in the body. While valuable, iPS cells are frequently generated from patients without a clear diagnosis of disease and many neurodegenerative diseases, such as AD, frequently lack specific and strong disease classification and severity grading. These diseases and their degree can only be definitively diagnosed by postmortem brain examinations. For the first time we will now be able to compare cells from living individuals to cells of patients with clear diagnoses generated from their banked brain tissue.

Brain bank networks, which combined contain tens of thousands of samples, offer a large and immediate source of tissue including rare disease samples and a conclusive spectrum of disease severity among samples. The difficulty of this strategy is that most of the biobanked brain tissue was not meant for growing live cells, and therefore was not frozen in the presence of cryoprotectants typically used to protect cells while frozen. NYSCF scientists in collaboration with CUMC scientists have shown that these thousands of samples can now be utilized to make living human cells for use in disease research and to develop new drugs or preventative treatments for future patients.

Related Links:

New York Stem Cell Foundation Research Institute
Columbia University Medical Center



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.